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Abstract:  Since  the  onset  of  antiviral  therapy,  viral  resistance  has  compromised  the 
clinical  value  of  small-molecule  drugs  targeting  pathogen  components.  As  intracellular 
parasites, viruses complete their life cycle by hijacking a multitude of host-factors. Aiming 
at the latter rather than the pathogen directly, host-directed antiviral therapy has emerged as 
a  concept  to  counteract  evolution  of  viral  resistance  and  develop  broad-spectrum  drug 
classes. This approach is propelled by bioinformatics analysis of genome-wide screens that 
greatly  enhance  insights  into  the  complex  network  of  host-pathogen  interactions  and 
generate a shortlist of potential gene targets from a multitude of candidates, thus setting the 
stage  for  a new  era of  rational  identification of drug targets  for host-directed antiviral 
therapies. With particular emphasis on human immunodeficiency virus and influenza virus, 
two  major  human  pathogens,  we  review  screens  employed  to  elucidate  host-pathogen 
interactions and discuss the state of database ontology approaches applicable to defining a 
therapeutic  endpoint.  The  value  of  this  strategy  for  drug  discovery  is  evaluated,  and 
perspectives for bioinformatics-driven hit identification are outlined.  
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1. Introduction 
With few exceptions, therapeutic approaches to combat infectious diseases have focused in the past 
decades on targeting unique components or enzymes of viral, bacterial and parasitic origin. It has now 
become perfectly evident that this traditional, pathogen-directed strategy, while highly successful in 
numerous cases [1], is inherently compromised by the rapid emergence of resistance or, increasingly, 
pre-existing  pathogen  resistance  to  individual  drugs.  For  example,  the  efficacy  of  current 
neuraminidase  inhibitors  for  the  treatment  of  pandemic  swine  origin  influenza  H1N1  isolates  is 
increasingly compromised by the appearance of viral strains with pre-existing resistance in the field [2–4]. 
Drug-resistant variants have likewise propelled the re-emergence of highly pathogenic bacteria strains 
such as Mycobacterium tuberculosis decades after they were considered contained [5,6]. 
Prompted  largely  by  the  onset  of  the  global  HIV  epidemic,  the  development  of  combination 
therapies based on drugs with distinct individual resistance profiles has considerably heightened the 
barrier against the development of pathogen resistance and frequently boosted the effectiveness of 
pathogen-directed  therapeutics  through  synergistic  effects  [7].  Despite  these  successes,  however, 
combination  therapies  have  not  conceptually  addressed  the  problem  of  pathogen  resistance  and 
multidrug  resistant  variants  that  emerge  frequently  in  clinical  settings  and  cohorts  of  highly  
therapy-experienced patients. Developing new generations of inhibitors that are inherently prohibitive 
of the rapid development of resistance will rather require a new and complementary paradigm for  
drug discovery. 
1.1. Host-Directed Antivirals, a New Paradigm for Management of Viral Diseases 
Of  the  strategies  entertained  towards  this  goal,  targeting  host  factors  that  are  essential  for  the 
pathogen  life  cycle,  rather  than  pathogen  components  directly,  has  recently  received  increasing 
attention [8–10]. While all pathogenic microbes experience interactions with their host organisms, 
viruses as obligatory parasites are directly dependent upon their host cell environment for replication, 
protein expression and assembly of progeny particles. It is anticipated that blocking one or more of 
these critical host components or cellular pathways will be resilient to the rapid development of viral 
resistance, since individual point mutations in viral components are unlikely to compensate for the loss 
of an essential host factor. 
Indeed, the currently available data for the experimental use of host cyclin-dependent kinase (CDK) 
inhibitors to block HSV-1 and HIV-1 replication, for instance, has revealed a remarkably reduced 
frequency of viral escape from inhibition in tissue culture settings [11,12]. In contrast, single point 
mutations  in  viral  components  are  fully  sufficient  to  abrogate  high-affinity  binding  of  pathogen-
directed antivirals as demonstrated by numerous studies investigating the molecular mechanism of 
viral  drug  resistance  [1].  Given  that  replication  of  related  viral  pathogens  frequently  depends  on Int. J. Mol. Sci. 2011, 12                       
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overlapping host cell pathways, host-directed antiviral strategies have high potential to move beyond 
the one-bug one-drug paradigm by broadening the pathogen target range of a chemical agent.  
1.2. Identification of Suitable Targets for Host-Directed Antivirals 
From a therapeutic perspective, the intricate and complex network of virus-host interactions yields a 
multitude of potential cellular targets for host-directed antivirals. In addition to the aforementioned 
role of CDK host protein kinases in HSV-1 and HIV-1 replication [11,12], some examples include 
regulatory kinases of the Abl [13] and Src [14] tyrosine kinase families, inhibition of which blocks 
poxvirus  motility  and  maturation  of  West  Nile  virus  particles,  respectively.  The  Raf/MEK/ERK 
kinases of the mitogen-activated protein kinase (MAPK) cascades [15], when inhibited, induce nuclear 
retention  of  the  influenza  virus  ribonucleoprotein  complexes  [16],  preventing  their  export 
and ultimately  influenza  virion  assembly.  A  further  example  includes  inhibition  of  COX-2,  a 
component of the eicosanoid biosynthesis pathway, which reduces yields of human cytomegalovirus 
progeny virus [17]. 
Clearly, the most desirable host target is essential for completion of the pathogen life cycle under 
investigation but at least temporarily dispensable for host cell survival, thus supporting the prospect 
that successful inhibition will combine a potent antiviral effect with manageable toxicity. Nevertheless, 
targeting host factors carries an inherently higher potential for undesirable drug-induced side effects 
than  pathogen-directed  antiviral  therapies,  particularly  when  the  latter  is  highly  selective.  While  
host-directed therapies are being explored for the treatment of some major chronic viral infections  
such as HSV-1 and HIV-1 [11,12], they appear predestined for the therapy of infections by pathogens 
predominantly associated with severe acute disease, since anticipated treatment times and concomitant 
host  exposure  to  the  drug  remain  limited.  On  the  other  hand,  chronic  infections  are  conceivably 
treatable by host-protein targets where more than one gene pathway regulates the condition. In some 
such cases, sequential application of host-gene modifiers could control disease progression without 
undue side effects associated with chronic application of an anti-viral drug.  
Hit candidates for host-directed drug development programs have resulted from a diverse set of 
experimental approaches. These can be grouped largely into knowledge-driven direct identification of 
individual targets, automated screening of chemical diversity sets with protocols specifically designed 
for  the  discovery  of  host-directed  hits,  and  systems-wide  screens  for  host  factors  essential  for  
pathogen replication.  
The  evolving  understanding  of  critical  host-pathogen  interactions  through  molecular  virology 
research of individual viral families has made possible the direct selection of candidate host targets. 
With an arsenal of approved and experimental therapeutics for inhibition of many cellular pathways  
at hand, identified candidate targets may in many cases be immediately testable through repurposing  
of  known  drugs  or  commercially  available  experimental  compounds  with  known  bioactivity.  The 
demonstration  that  Gleevec  (Imatinib  mesylate),  an  Abl  tyrosine  kinase  inhibitor  licensed  for  the 
treatment of several cancer forms [18], is a poxvirus blocker [13] and the repurposing of the MEK 
kinase inhibitor U0126 to block the Raf/MEK/ERK cascade for influenza virus inhibition [16,19] serve 
as cases in point. While the former originated from the insight that efficient vaccinia virus spread 
requires phosphorylation of the viral A36R protein by Abl and Src family tyrosine kinases [20,21], the Int. J. Mol. Sci. 2011, 12                       
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latter was triggered by the observation that influenza virus infection induces the activation of MAPK 
family members [16,21]. 
The availability of large robotic capacities in both corporate and academic settings combined with 
the rapid design and production of small-molecule compound libraries in the past two decades has 
accelerated the pace of discovery of novel drug candidates via high-throughput screening exercises. 
Applied to the identification of antiviral hits with a host-directed activity profile, for instance, it should 
be feasible to derive suitable screening protocols based on the hypothesis that host-directed candidates 
will  likely  show  some  cellular  interference  and  return  a  broadened  pathogen  target  range.  While  
the  former  will  translate  into  a  lower  primary  screening  score  represented  by  the  selectivity 
index (CC50/EC50), the latter should result in efficient inhibition not only of the screening agent but 
also  of  pathogens  of  related  viral  families  when  assessed  in  counter-screening  assays.  When  we 
explored the general feasibility of this approach conceptually using a ~140,000-entry diversity set, 
several  chemical  compound  classes  were  identified  that  efficiently  blocked  replication  of  a  panel 
of distinct  members  of  the  myxovirus  families  [22].  Significantly,  a  subset  of  these  revealed  a  
host-directed activity profile in secondary assays and counter-screening exercises.  
To  determine  the  molecular  target  of  host-directed  compounds  identified  through  screening  of 
chemical  libraries,  a  combination of traditional mechanism of action studies,  genomics  (i.e.,  gene 
microarrays), and/or proteomics (i.e., protein profiling) studies is conceivable. Target identification not 
only sets the stage for possible knowledge-based scaffold optimization through rationale design in 
conjunction with hit-to-lead chemistry or repurposing of known inhibitors with identical target profile, 
but also contributes to further elucidating critical pathogen host interactions and, thus, basic insight 
into pathogen biology.  
A second unbiased approach for host-target identification centers on screens for host factors directly 
interacting with viral components or required for successful completion of the viral life cycle. Of these, 
avidity-based extracellular interaction screens (AVEXIS) of protein-protein contacts [23] and yeast 
two-hybrid  screens  [24,25]  appear  promising,  although  they  remain  inherently  limited  to  specific 
pathogen factors selected as ―baits‖. In contrast, loss-of-function screens based on aptamers [26,27] or 
antisense RNA interference [28–31] and gain-of-function approaches utilizing expression libraries [32,33] 
afford a systems-wide view of host-factors essential for pathogen replication or boosting pathogen 
success,  respectively.  In  recent  years,  groundbreaking  ―loss-of-function‖  antisense  screens  were 
carried  out  for  major  viral  pathogens  including  influenza  virus  [34,35],  human  immunodeficiency  
virus (HIV) [36–39] West Nile virus [40] and hepatitis C virus [41]. These have transformed our 
understanding of the virus-host interplay.  
Surprisingly, however, independent  large-scale screens  directed  at  influenza virus, for instance, 
returned very little redundancy for essential host factors identified. This suggests that the screening 
efforts still lack saturation, and that cross-study bioinformatics efforts for data mining would benefit 
significantly by commencing on a host cell pathway rather than at the individual protein level. When a 
set of identified pathways essential for virus replication  emerges through bioinformatics selection, 
individual components  can be subjected to  secondary screens  using known drugs  or  experimental 
inhibitors  to  short-list  desirable  individual  targets.  A  proposed  workflow  for  a  bioinformatics  
lead-identification process is displayed in Figure 1. In the following, we will discuss in detail the Int. J. Mol. Sci. 2011, 12                       
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current state of data mining approaches and how they have been, or could be, applied to screening 
results reported for HIV-1 and influenza A viruses.  
Figure 1. RNAi-Based Lead Identification Workflow. Aberrant expressed genes identified 
in the RNAi screen are categorized into clusters based on biological function. Members of 
the  largest  clusters  are  literature  and  database-mined  for  known  small  molecule 
modulators.  Candidate  inhibitors  are  subjected  to  biotesting  for  hit  confirmation.  This 
review focuses on the ability of bioinformatics methods to identify potential medicinal  
lead compounds. 
 
2. Methods to Analyze and Process Viral Host Factors Identified as Hits 
As with the output of chemical genomic screens, genome-wide association studies (GWAS) require 
bioinformatics support to analyze high density data points and highlight the important gene or gene 
sets responsible for the phenotype under investigation. False positives need attention beyond the high 
throughput experiment when choosing targets for further study. These data points often arise when 
certain  genes  have  been  incorrectly  identified  due  to  off-target  effects  associated  with  siRNA 
inhibition. In one case, a single siRNA reportedly perturbed the expression of over 300 genes [42]. The 
potential quantity of false positives  generated from a single RNAi  screening experiment  becomes 
alarming, when a single RNAi can potentially affect a large subset of gene expressions. It has been 
hypothesized that clustering methods such as pathway analysis and gene functional analysis are a 
possible means to discard false positives and highlight true positives, since they readily generate a 
biological interpretation of a high throughput result. A number of reviews have summarized the state 
of genetic analysis [43–51]. In this article, we outline the GWAS approach to antiviral identification 
and then highlight how such methods have been used to probe host-virus interactions. 
Currently, several curated databases in the public domain detail known gene product associations (see 
Table 1 for examples). As will be illustrated in the following, different databases may return a diverse 
set of answers even when identical RNAi screening results are used as input.  Int. J. Mol. Sci. 2011, 12                       
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Table 1. Commercial and open source pathway databases. 
Database  Description  References 
Kyoto Encyclopedia of 
Genes and Genome 
(KEGG) 
Public Resource links genes to crystal structures and drugs 
when information is available 
[52–54] 
Reactome 
Public Resource accepts a gene list for the pathway 
analyzer and returns percentage population per pathway 
[55–57] 
Protein Analysis 
Through Evolutionary 
Relationships 
(PANTHER) 
Free pathway database allows user to identify enrichment 
in biological pathways, GO terms or protein class 
[58,59] 
WikiPathways  Community curated pathway database  [60,61] 
Ingenuity IPA 
Commercial pathway database to identify enrichment in 
pathways/GO terms; links drugs to specific genes 
[62] 
Gene Ontology (GO) 
Consortium 
Community database that clusters genes by biological 
process, molecular function or cellular location across 
multiple species 
[63] 
Search Tool for the 
Retrieval of Interacting 
Genes/Proteins 
(STRING) 
Freely available functional relationships database displays 
direct neighborhood relationships between proteins that 
interact directly or through an intermediary  
[64–69] 
Search Tool for 
Interactions of 
Chemicals (STITCH) 
Crosslinks gene products with chemical structures from 
PubChem 
[70,71] 
GeneGo Metacore 
Commercial manually curated pathway database annotated 
with 600,000 compounds 
[72] 
Prolexys HyNet 
Commercial database protein-protein interaction identified 
via in-house yeast two-hybrid screening 
[73] 
Biomolecular Interaction 
Network Database 
(BIND) 
Free and Commercial versions describing  
protein-protein interactions, molecular complexes and 
pathways 
[74,75] 
Molecular Interactions 
Database (MINT) 
Public protein-protein interaction database based on peer-
reviewed literature. Accessible through  
web-interface or Simple Object Access 
Protocol/Representational State Transfer (SOAP/REST) 
protocols 
[76] 
Human Protein 
Reference Database 
(HPRD) 
Public proteonomic database with descriptions for 2750 
human proteins taken from the primary literature  
[77–79] 
Application of GWAS frequently employs graphical networks displaying interconnected genes as 
exemplified in Figure 2. The ability to interconnect and cluster genes by known function forgoes the 
need to verify every target that is generated by an RNAi screen through a multitude of single biological 
experiments. Topological representations of biological function identify enriched regions of perturbed 
gene expression and their relevant cellular operations. Usefulness of gene enrichment analyses depends Int. J. Mol. Sci. 2011, 12                       
 
 
4033 
on the quality of the database used [80]. If accurate, gene enrichment separates genes from those that 
were randomly identified during the RNAi screening and offers the largest source of antiviral target 
candidates for drug development, based on the assumption that all members of an enriched region are 
required for efficient viral replication. The fundamentals of network theory and its usage in GWAS 
analysis  are  reviewed  in  [80].  Gene  expression  studies  can  utilize  enhanced  methods  of  pathway 
analysis which go beyond treating pathways as simple sets of genes and incorporate the complex gene 
interactions  described  by  the  pathway,  such  as  measurement  of  total  pathway  perturbation  [81]. 
Unfortunately  such  methods  require  quantitative  differential  expression  data  to  be  applicable,  a 
component lacking in these RNAi screening studies. It is possible, however, that inclusion of RNAi 
viral inhibition data in a modified version of this enhanced method might lead to improvement in 
pathway enrichment, but this is yet to be exemplified in the literature.  
Figure  2.  Network  Association  Map  of  RNAi  screening  results  generated  by  the  
Brass et al. influenza virus infection. The list of perturbed host cell genes were complied in 
STRING and illustrated as nodes above. Lines between different nodes (edges) represent 
protein  interactions  that  are  either  known  experimentally  (purple)  or  predicted 
computationally  (yellow).  Significant  nodes  such  as  those  shown  around  COPA  and 
CRNLK1 suggest these pathways to be critical for the viral life cycle. 
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Thus,  pathway  analysis  and  gene  function  annotation  offer  the  drug  screening  community 
automated procedures for extracting meaning from a large array of differentially expressed genes. The 
identified genes can be grouped according to the relationships among protein products, while potential 
drug targets associated with enriched pathways can be perceived. 
An illustration of the identification of therapeutic compounds by means of bioinformatics analysis 
is  the  use  of  a  gene  list  to  link  Tamoxifen  to  the  treatment  of  Systemic  Lupus  Erythematosus  
(SLE) [82–84]. Investigators discovered that the estrogen receptor pathway is a significantly enriched 
gene category with respect to a list of SLE’s aberrantly expressed genes through the Disease-Drug 
Correlation Ontology (DDCO). Other databases that similarly infuse  chemical knowledge into the 
pathway databases include KEGG, the Connectivity Map, Ingenuity IPA and the STITCH database (all 
of which are also included in Table 1). Figure 3 offers an example of a gene interaction map annotated 
with small molecules. 
Figure 3. Gene interaction map overlapped with Tamoxifen via the STITCH database. The 
latter also connects ovals to one another suggesting that these molecules display similar 
biological behavior towards the same target. Edges refer to interactions as determined by 
experiment (purple), manual curation (cyan) or computationally predictions (yellow).  
 
While  the  previously  cited  resources  offer  investigators  utmost  convenience  in  immediately 
accessing lists of available small molecule modulators related to a pathway of interest, other databases 
connect small molecule modulators with known protein targets. These require a separate pathway 
analysis  to  choose  a  particular  set  of  gene  products  of  interest.  Suitable  resources  include  
DrugBank  [85,86],  PDB/sc-PDB  [87–89],  PubChem  [90],  Sunset  Molecular’s  WOMBAT-PK  
2010 [91,92] and the BRENDA database [93]. 
Following  a  bioinformatics  selection  of  target  candidates,  individual  targets  must  be  selected  
for medicinal chemistry, for instance, based on the previous discovery of small-molecule blockers  Int. J. Mol. Sci. 2011, 12                       
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or the availability of crystal structures in the Protein Data Bank (PDB). [88,89]. Then, de novo drug 
discovery can be sustained through 3D virtual screening [94] and structure-based design. Application 
of these methods to the analysis of HIV and flu RNAi screens will be discussed in the next section. 
3. Bioinformatics Approaches for Identifying Host-Factors Required for HIV Replication  
Each  of  the  systematic  studies  examined  in  the  following  sections  employed  a  unique 
bioinformatics approach to pathway analysis. Similar to a chemoinformatics clustering analysis of a 
high-throughput  screen  to  short-list  a set  of  chemical  leads  for  optimization,  a  goal  of  the  RNAi 
screening studies is to identify, by means of gene pathway or functional analysis, potential host factor 
targets that are essential for viral replication. A key question is whether the resulting bioinformatics 
short list of host factors contains suitable candidates for drug development. 
3.1. Bioinformatics Approaches to Identify Host-Factors Required for HIV Virus Replication 
For HIV, three independent siRNA studies were published in 2008 by Brass et al. [36], Konig et al. [95] 
and  Zhou  et  al.  [37].  All  three  siRNA  studies  utilized  the  National  Center  for  Biotechnology 
Information  (NCBI)  database  of  HIV-1  and  human  protein  interactions  (currently  1443  proteins 
identified) to evaluate the overlap of hit genes with the curated virus-host interactions available in the 
NCBI database [61]. Figure 4 illustrates the total number of genes found as well as the pairwise 
overlap between genes in each study. A meta-analysis of these genome-wide studies was subsequently 
performed by Bushman et al. in 2009 [96]. 
Figure 4. Illustration of the pairwise overlap between hit genes in the three HIV siRNA 
studies and the NCBI database. Circle areas are proportional to the number of genes. For 
clarity, three-way and higher overlaps are not shown. 
 Int. J. Mol. Sci. 2011, 12                       
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Bushman et al. performed an overlap analysis/random distribution comparison based on these data 
and found associations that were statistically significant (p-values < 0.001). While one may safely 
assume that the hit genes are enriched with respect to independently identified and confirmed host 
factors required for HIV-1 replication, pairwise overlaps between the studies are low, ranging only 
from 3 to 6%. While these were still judged statistically significant (p-values < 0.024 for all pairs) [96],  
the overall very low redundancy suggests considerable experimental variability associated with each 
siRNA screen. 
Variation  in  individual host  factors  could  be  accounted  for  by  a  number  of  factors,  including: 
(a) high experimental variance of siRNA transfection efficiencies [42]; (b) harvest of cells at different 
time points post-infection; (c) the use of different analysis methods and filtering thresholds; (d) an 
inherent bias of individual assays towards specific stages of the viral life cycle [96]; and (e) overall 
moderate  reproducibility  of  siRNA-based  screens[97].  Some  of  these  variances  might  be  readily 
controlled by additional replicates examined per screen. For instance, only the study by Konig et al. 
performed the screen in duplicate. As a case in point, the experimental data showed large variances 
between the replicates: 24% of hit siRNAs (141) exhibit standard deviations greater than 25% of their 
median values. Furthermore, Bushman et al. demonstrated that adjusting the filtering thresholds in this 
study strongly influences the nature of the identified genes (shown Figure 1D of Bushman et al.) [96]. 
Other parameters, such  as  non-uniform  harvesting time points,  are inherent  to  the design of  each 
individual study and cannot be standardized retroactively. Although capturing different stages of the 
viral life cycle in separate studies may ultimately be necessary to fully appreciate the scope of the  
host-pathogen interaction network, different analysis times should be considered as a major contributor 
to the low level of congruity between the currently available data.  
Independent of redundancy between studies, the question remains of whether the gene hits represent 
bona  fide  host  factors  required  for  HIV  replication  or  false  positives  that  may  have  arisen  from 
experimental variability. Equally important for hit confirmation is the organization of the data sets into 
groups by gene function and cellular pathways to illuminate distinct parts of the intricate host-pathogen 
interaction  network.  Using  terms  from  the  Gene  Ontology  (GO)  database  Brass  et  al.  noted  that  
103  of  their  hit  genes  were  assigned  with  136  statistically  significant  (p-value  <  0.05)  biological  
processes [36]. In brief, the GO database is a consortium established to relate genes to one another in a 
fixed  file  format  within  three  categories:  biological  processes,  cellular  components  and  molecular 
functions [44,63,98,99]. To reduce redundancy, these categories were clustered and manually curated. 
GO analysis yielded 17 enriched cellular functions in the Brass HIV study. Alternatively, the Zhou 
study  used  Ingenuity  Pathway  Analysis  to  determine  enriched  molecular  functions  and  biological 
pathways. Thirty-two molecular functions were identified, and twelve biological processes were found 
to be statistically significant (p-value < 0.05). 
In contrast, Konig and colleagues employed a multi-tiered bioinformatics approach to identify the 
host factors most important to HIV replication through the use of the Prolexys HyNet database [95]. 
This resulted in networks of 2468, 4080, and 2850 genes in the HIV, MLV, AAV and toxicity assays, 
respectively. Using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [100], 
the Konig team extracted overrepresented functional clusters for all genes found in the three HIV 
siRNA studies. Filtering for significance (p-value < 0.06 based on a geometric mean for all the terms 
in a group), redundancy, biological relevance and specificity returned 24 functional groups (A listing Int. J. Mol. Sci. 2011, 12                       
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of the overlapping pathways and those identified uniquely are presented in Figure 5), most of which 
contained genes that were identified in two or more studies. Although each study contains a significant 
number of genes that may be defined by molecular functions common to each of the three studies, 
consistent function identification across the siRNA screens is lacking due to the distinctions in each 
study’s bioinformatics methods. These functions may be defined differently between methods due to 
redundancies present in each database. Slightly different but biologically meaningless distinctions can 
arise thereby.  
Figure 5. Comparison of HIV-dependent host functions identified by Bushman et al. [96], 
Brass et al. [36], Konig et al. [95] and Zhou et al. [37]. Grey boxes indicate functions 
unique to an individual study. 
 
Although some well-documented host factors required for HIV replication (such as CD4, CXCR4, 
NFκB subunit RELA, activating kinases AKT1 and JAK1, TSG101, and various cofactors of Vpr, Vif, 
Tat, and Rev) [101–105] were identified in at least one of the three siRNA studies, a variety of other 
host factors known to engage with HIV (HLA-B57, HLA-C, PSIP1/LEDBF/p75, Sp1, cyclophilin A, 
ITGB1,  ITGB2,  and  ITGB3)  were  not  discovered  [96,106–115].  Of  these,  the  absence  of  the 
integration cofactor PSIP1/LEDBF/p75, HIV long terminal repeat transcription factor Sp1, HIV Gag 
binding  protein  cyclophilin  A,  and  the  three  integrin  proteins  (ITBG1,  ITBG2,  ITBG3)  is  most 
noticeable. [108–112,114–117] These results suggest that even a combined host factor analysis is at 
risk of missing key host components required for viral replication. Furthermore, no single siRNA study 
thus far illuminates all relevant, and currently known, cellular factors associated with the pathogen. 
The  meta-analysis  was  extended  by  building  an  HIV-host  factor  interaction  network  of  1657 
cellular proteins using an array of protein-protein interaction databases (BIND, HPRD, MINT, and Int. J. Mol. Sci. 2011, 12                       
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Reactome) [96]. With MCODE’s graph theoretic clustering algorithm, clusters within this interactome 
map having different functions were identified. Of the 11 clusters found, 10 were associated with 
distinct cellular functions: the proteasome, transcription/RNA polymerase, the mediator complex, Tat 
activation/transcriptional elongation, RNA Binding/Splicing, BiP/GRP78/HSPA5 Chaperone, and CCT 
Chaperone. From a drug discovery perspective, however, small molecule testing or counter-screening 
with individual siRNAs against target candidates are required to validate individual pathways. 
Lack of saturation in host genes identified through current siRNA screens, varying consistency and 
high overlap of genes in specific areas emerge as future challenges for application to system-wide drug 
discovery efforts.  
3.2. Bioinformatics Approaches to Identify Host-Factors Required for Influenza Virus Replication 
In addition to application of system-wide siRNA screens to the HIV system, the technology was 
applied to the influenza virus. Major siRNA studies were reported by Hao et al. [118], Brass et al. [119], 
Shapira et al. [120], Konig et al. [34] and Karlas et al. [35]. Other types of screens were performed by 
Josset et al. [121], which identified a gene list based on gene expression response to influenza; and 
Coombs et al. [122], which performed a quantitative analysis of protein level changes in infected cells. 
While Hao and colleagues employed a Drosophila cell-based host system for their siRNA screens, both 
Konig and Karlas relied on human lung cells (A549) and the influenza A/WSN (H1N1) strain or a 
recombinant variant thereof. Brass and colleagues used a human osteosarcoma cell system (U2OS) and 
the influenza A/PR/8 (H1N1) strain. The Shapira study is unique in that it combined results for yeast 
two- hybrid analyses, genome-wide transcriptional gene expression profiling and siRNA screening. 
Unfortunately,  a  single  publically  available  resource  similar  to  the  NIH/NIAID  HIV-1  interaction 
database does not exist for influenza virus, although many distinct virus-host interactions have been 
described in the literature (reviewed in [123]). 
Watanabe  et  al.  summarized  five  of  the  six  systematic  studies  reported  above  and  performed 
bioinformatics analysis on the 1,449 identified genes required for influenza replication [123]. Much 
like the Bushman et al. analysis of HIV host factors [96], 128 genes were found in multiple screens 
when pairwise comparisons were performed. The highest pairwise overlap (32 genes) is found in the 
Konig et al. and Karlas et al. studies, possibly due to the overlaps in host cell type (A549 cells) and 
influenza virus strain (A/WSN (H1N1)). This lack of overlap is also illustrated in the pairwise analysis 
given  in  Table  S1.  Unlike  the  meta-analysis  for  the  HIV  studies  discussed  above,  this  pairwise 
comparison  lacked  random  distribution  simulations,  preventing  the  assessment  of  statistical 
significance. Nevertheless, the observed low overlap rate most likely results from factors similar to 
those discussed above for the HIV siRNA studies, i.e., different harvest times, detection thresholds and 
host cell lines, coupled with the additional complication of variability introduced through the use of 
different viral strains. 
As  described  in  the  HIV  siRNA  analyses,  each  study  examining  influenza  virus  infections 
performed  individual  bioinformatics  analyses  on  siRNA  screening  results.  A  summary  of  these 
bioinformatics data along with the methodology is reviewed by Min [124]. In unique congruence, three 
of  the  influenza  virus  studies  explored  the  use  of  known  small-molecule  inhibitors  to  obtain Int. J. Mol. Sci. 2011, 12                       
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independent proof-of-concept for the importance of cellular targets identified by bioinformatics for 
virus replication [34,35,121]. 
Konig  reported  six  compounds  with  EC50  values  ranging  from  0.5  to  30  μM  target  FRAP1, 
HSP90AA1, TUBB, FGFR4,  GSK3B, or ANPEP.  Of these, FRAP1,  TUBB, FGFR4 and GSK3B 
home to the same GO Term cluster, protein kinase activity, recommending it as a potentially rich 
source for influenza virus inhibitors. The cytosolic chaperone Hsp90AAP1 was identified in a separate 
GO  Term  cluster;  interestingly,  previous  reports  have  already  established  a  link  to  influenza  
virus [125] and HCV [126] replication. The Karlas study reported another efficacious small molecule 
inhibitor,  TG003,  which  targets  the  CDC-like  kinase  1  (CLK1).  CLK1  was  retrieved  from  the 
Spliceosome GO term cluster, where it ranked seventh in significance among the list of enriched 
cellular components.  
While the above studies identified potential host factor targets through GO term enrichment and 
then  followed  up  with  small  molecules  available  for  viral  testing,  the  Josset  project  searched 
Connectivity Map with 20 of the most perturbed genes from the 300 initially identified. Of the eight 
compounds available through commercial vendors, six attenuated influenza virus replication with EC50 
values ranging from 5.8 to 30 μM. In-house analysis of the 20 genes used to identify these compounds 
revealed that they are significantly enriched in metabolic processes. Similar to previous studies, the 
Josset report does not explicitly identify a host pathway essential for viral replication based on the 
small molecule inhibition studies. To appreciate the full potential of this approach for antiviral drug 
development, it may be informative to collect all known inhibitors of a particular host pathway and 
determine the complete extent of virus inhibition.  
Watanabe et al. performed a meta-analysis of the siRNA results using the set of 128 genes found in 
two or more studies [123]. The major gene categories were determined through PANTHER, a database 
that also utilizes GO terms to organize gene lists. Several molecular functions were found significant: 
nucleic acid-binding proteins, kinases, transcription factors, ribosomal proteins, hydrogen transporters 
and proteins related to mRNA splicing. Biological processes found to be consequential were protein 
metabolism and modification, signal transduction, protein phosphorylation, nucleoside, nucleotide and 
nucleic acid metabolism and intracellular transport. Reactome analysis tagged as significant eukaryotic 
translation initiation, regulation of gene expression, processing of capped intron-containing pre-mRNAs 
and  Golgi-to-ER  retrograde  transport.  This  set  of  128  genes  was  further  integrated  with  the  viral 
protein interaction partners determined by Konig and Shapira, resulting in a network of virus-host 
interactions. Based on this map, MCODE further identified translation initiation, mRNA processing 
and proton-transport as crucial. Accordingly, mining of the top MCODE cluster in Figure 6 predicts 
that  compounds  such  as  spectoinomycin,  emetine  and  quercetin  will  interfere  with  influenza  
virus replication. 
Successful  outcomes  for  bioinformatics  searches  predominantly  depend  on  the  accuracy  of 
tabulated database interactions. As detailed below, use of different databases may alter the profile of 
pathways that are enriched from the same gene list. In such cases, users are obligated to formulate a 
realistic biological interpretation of the relational data to ensure identification of meaningful candidate 
compounds for an antiviral drug program. Int. J. Mol. Sci. 2011, 12                       
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Figure 6. Small molecule (ovals) identification of gene products (spheres) associated with 
translation initiation. Green edges represent protein-ligand interactions. These compounds 
have not been reported previously to interfere with influenza infection, although quercetin 
has been demonstrated to attenuate HCV, however through a different host factor [126]. 
 
4. Pathway Database Comparisons: Same Source, Different Interpretation 
As outlined above, it is a primary function of gene databases to extract biological meaning as well 
as potential therapeutic host factors from a high throughput RNAi screen by means of descriptive 
annotations  of  genes  common  to  a  particular  biological  pathway  or  gene  function.  In  the  realm  
of  antiviral  drug  discovery,  this  approach  aims  at  identifying  host  cell  components  critical  for  
virus replication. 
Crucial  for  the  success  of  this  strategy  is  the  quality  of  the  pathway  database  used,  which  is 
determined  by  the  curation  method  of  published  experimental  data  of  gene  associations  and  the 
expertise of the curators involved. Soh et al. have demonstrated that inconsistencies emerge when gene 
association data are compared across different pathways databases [127]. This came as a surprise, 
since most databases  share published literature  as  a data source, suggesting that methodology  for 
curation and criteria for gene associations were not uniform (for this study, the Ingenuity IPA, KEGG, 
and  Wikipathways  databases  were  compared).  Assuming  curation  is  performed  on  available 
literature data, however, one expects similar genes and gene pairs to be found across the different 
databases. (Gene pairings are defined as gene product associations confirmed by the database curator).  Int. J. Mol. Sci. 2011, 12                       
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The Wnt signaling pathway provides a tangible example illustrating the current challenges. This 
pathway has been implicated in therapeutic interference with cancer and viral entry. Two-way analyses 
revealed  approximately  80%  gene  similarity  when  based  on  the  KEGG  and  Wikipathways 
databases (Table 4 in [127]). However, only 43% similarity is found when Ingenuity and KEGG are 
examined  (Table  3  in  [127]),  while  comparison  of  Ingenuity  and  Wikipathways  databases  returns  
only  28% similarity (Table 5 in [127]). Inconsistencies across databases are even more disconcerting  
when  gene pair  overlaps  are  examined:  KEGG/Wikipathways  (18%),  Ingenuity/KEGG  (8%), 
Ingenuity/Wikipathways (0%). It is the quality of the gene pairing data in each database, however, that 
allows end users to triage the multiple RNAi screening results for pathway congruity.  
Looking  on  a  broader  scale  across  26  cellular  pathways  described  in  Soh  et  al.,  gene  overlap 
similarity has a mean value of 66.5% when comparing the KEGG database and Wikipathways [127]. 
By contrast, the mean values of similarity for Ingenuity/KEGG and Ingenuity/Wikipathways  were 
53.8% (12 pathway categories) and 41% (11 pathway categories), respectively. Despite the higher 
gene overlap between KEGG and Wikipathways, the pairing overlap is still only approximately 50% 
for any listed pathway compared across any three of the databases. KEGG is curated by a single  
lab group, while Wikipathways is curated through a community effort. At the moment, it is not clear  
to what extent the curation procedures contribute to the highly variable data mismatches. However, 
there is little doubt that this and other variables would benefit from cross-consolidation between the  
various databases.  
Soh et al. also analyzed the comprehensiveness of the databases, which was a measure for the total 
number of genes from all three databases [127]. This was followed by evaluation of gene members and 
pairings  of each database against the pool,  which consisted of 21,314 genes  and 60,900 pairings. 
KEGG was shown to be the most comprehensive of the three databases, but this was influenced by  
the  result  of  KEGG’s  inclusion  of  metabolic  pathways  specifically  not  curated  by  either  of  the  
other databases.  
Concentrating in particular on viral host factors, we performed an in-house analysis that compares 
host proteins involved in the influenza virus life cycle across various databases. Databases used in this 
example  included  Reactome,  Ingenuity  IPA  and  PANTHER.  The  Reactome  database  records  six  
host  factor  genes  for  influenza  in  each  the  categories  associated  with  NS1-mediated  effects  and  
virus-induced apoptosis. Databases such as Ingenuity IPA and PANTHER lack pathway categories 
dedicated to influenza virus. Keyword searches for influenza in the PANTHER database identified no 
host  factor  associated  with  influenza  virus  infection  [58].  Conversely,  keyword  searching  of  the 
Ingenuity database generated a list of five signaling pathways (Lipids/Lipid Rafts, MAPK, PI3K/AKT, 
Wnt/GSK-3β, hypercytokinemia) involved in the pathogenesis of influenza virus, constituting a list of 
38 genes [128]. Import of the latter into all other databases allows the genes to be categorized into 
signaling  pathways  such  as  Wnt,  PI3K,  and  MAPK.  However,  database  annotations  suggest  that 
Ingenuity is more likely to alert the user to the genes’ roles in influenza virus infection.  
Applying this approach to the previously described influenza RNAi screens, we sought to address 
the question of how does target identification change when different pathway databases are applied to 
the same dataset? Databases used in this comparison were PANTHER, Reactome and STRING, and 
the data set analyzed was the commonly identified 128 gene list generated by Watanabe et al. [123]. 
Results are presented in Table 2 with reference to the Wanatabe analysis of the same genes. Int. J. Mol. Sci. 2011, 12                       
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Table 2. Comparison of pathway results from the Watanabe pairwise influenza gene set. 
GeneGO/MCODE  STRING  PANTHER  Ingenuity IPA  Reactome 
Translation 
Initiation 
Translation 
Initiation 
Apoptosis signaling 
pathway 
Chronic Myeloid  
Leukemia Signaling 
Dissolution of Fibrin  
Clot 
Pre-mRNA 
Processing 
Pre-mRNA 
Processing 
T cell activation 
B Cell Receptor  
Signaling 
Influenza Life Cycle 
Proton-Transporter  
V-type ATPase 
Proton-
Transporter  
V-type ATPase 
Angiogenesis 
Production of Nitric 
Oxide and Reactive  
Oxygen Species in 
Macrophages 
MAP kinase cascade 
 
COPI coating 
of Golgi vesicle 
Toll receptor signaling   EIF2 Signaling 
Metabolism of nitric  
oxide 
 
Nuclear 
Transport 
Inflammation mediated 
by chemokine and 
cytokine signaling 
pathways 
Rank Signaling  
in Osteoclast 
Eukaryotic 
Translation  
Initiation 
     Cell cycle  CD40 Signaling  Signaling by FGFR 
     PDGF signaling  
Molecular 
Mechanisms  
of Cancer 
Eukaryotic 
Translation  
Termination 
     FGF signaling  
Role of PKR in 
Interferon Induction  
and Antiviral 
Response 
Eukaryotic 
Translation  
Elongation 
     FAS signaling     
Regulation of  
beta-cell  
development 
     Ras Pathway    
Signaling by Insulin  
receptor 
     B cell activation    
Processing  
of Capped  
Intron-Containing  
Pre-mRNA 
It becomes immediately obvious when examining the most enriched pathways that only the STRING 
database seems to reproduce the results generated by Watanabe et al. using GeneGO/MCODE. In all 
other cases, the different databases returned remarkably different top pathways when the same gene 
expression set was analyzed. Closer examination reveals that that other top ranking pathways (i.e., 
translation initiation) rank lower on the Reactome enrichment analysis scale. Pathways associated with 
B-Cell  metabolism  are  also  identified  by  the  Ingenuity  IPA  and  Reactome  enrichments,  although 
slightly different naming schemes are used. Since discrete databases identify certain similar pathways 
at different rankings, a consensus scoring function applicable to available databases appears warranted. 
This would afford greater confidence in the identification of individual targets for follow-up through 
small molecule searching. Int. J. Mol. Sci. 2011, 12                       
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5. Conclusions 
Previous GWAS experiments have attempted to capture the most relevant cellular host pathways 
utilized by pathogens such as HIV and influenza virus for virus replication [96,123]. As shown by 
reviewers such as Bushman et al. and Watanabe et al., gene lists and enriched pathways vary widely 
despite the pursuit of similar biological goals. Indeed, the likelihood to successfully identify novel 
host-directed antivirals would increase significantly if the reproducibility of individual RNAi screens 
were to be increased [97]. Further challenges emerge from differently curated pathway databases that 
return unrelated enriched pathways based on analysis of the same gene data set. Preliminary analysis 
of this situation using the Watanabe 128 pairwise genes suggests that a consensus scoring protocol 
applicable across different databases would be desirable to clarify this issue. Despite these hurdles 
associated with experimental false positives and the complexities inherent in interpreting pairwise gene 
interactions, several tangible examples (i.e., Konig et al., Karlas et al., and Josset et al.) demonstrate 
that RNAi screening coupled with bioinformatics-driven triaging is a viable method to identify small 
molecule inhibitors of virus replication. 
Current databases that infuse chemical knowledge into schemes such as Ingenuity IPA and the 
Connectivity Map are limited to a small number of compounds, mostly FDA-approved drugs. This 
narrow focus limits their application to current translational medicine. The STITCH database makes an 
interesting leap by crosslinking its gene network with multiple chemical-genomic high throughput 
screening  results  archived  in  PubChem.  These  experimental  chemicals  along  with  compounds 
currently tested in vitro for various endpoints offer a rich source for hit candidates with optimization 
potential. As more databases are used to analyze potential host targets, validation methods employing 
siRNA are improved and small molecule knowledge is added to the genetic web, more drug discovery 
initiatives  are  likely  to  incorporate  this  approach  in  their  portfolio  of  standard  operations  for  the 
identification of antiviral therapeutics. 
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